P&T Cmtes. Need Incentives To Use Cost-Effectiveness Analyses – MedPAC
Executive Summary
Medicare prescription drug plan pharmacy & therapeutics committees should be given incentives for using cost-effectiveness analyses to develop formularies, Medicare Payment Advisory Commission member Alan Nelson suggested during a March 12 meeting in Washington D.C
You may also be interested in...
U.S. Should Create Cost-Effectiveness Group To Advise CMS – NEJM Editorial
The U.S. government should establish an entity similar to the U.K.'s National Institute for Clinical Excellence to help CMS apply cost-effectiveness criteria to coverage and payment decisions, an editorial in the Oct. 6 New England Journal of Medicine states.
U.S. Should Create Cost-Effectiveness Group To Advise CMS – NEJM Editorial
The U.S. government should establish an entity similar to the U.K.'s National Institute for Clinical Excellence to help CMS apply cost-effectiveness criteria to coverage and payment decisions, an editorial in the Oct. 6 New England Journal of Medicine states.
Medicare P&T Committees Can Consider Costs, But Only In Broad Context
Medicare prescription drug plan pharmacy & therapeutics committees must consider the overall economic impact of coverage decisions - not just pharmacy costs - if they use pharmacoeconomic data in their analyses, the Centers for Medicare & Medicaid Services states in its final rule implementing Title I of the Medicare Modernization Act